Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.54, $0.01 better than the analyst estimate of $0.53. Revenue for the quarter came in at $28.7 million versus the consensus estimate of $27.84 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.